SYK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Stryker Corp (SYK) is not a strong buy at this moment for a beginner investor with a long-term focus. While the company has strong financial performance and positive growth prospects, the recent cybersecurity incident, hedge fund selling trends, and mixed analyst sentiment suggest caution. Additionally, technical indicators and options data do not signal a compelling entry point.
The MACD is above 0 and positively contracting, indicating mild bullish momentum. RSI is neutral at 47.526, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 338.507, with resistance at 349.499 and support at 327.515.
Acquisition of Amplitude Vascular Systems to enhance the peripheral vascular business.
Strong financial performance in Q4 2025, with revenue up 11.42% YoY and net income up 55.49% YoY.
Analysts highlight Stryker's high-quality growth and strong product portfolio.
Cybersecurity incident impacting Q1 2026 operations and financials, with ongoing investigations into potential fiduciary breaches.
Hedge funds are selling, with a 119.77% increase in selling activity over the last quarter.
Analysts have recently lowered price targets, citing uncertainty around Q1 performance and the cybersecurity attack.
In Q4 2025, Stryker reported revenue growth of 11.42% YoY to $7.171 billion, net income growth of 55.49% YoY to $849 million, and EPS growth of 56.03% YoY to $2.2. However, gross margin slightly declined by 0.46% YoY to 62.61%.
Analysts have mixed views. While some maintain Buy or Outperform ratings, others have lowered price targets, citing concerns about Q1 performance and the cybersecurity incident. Price targets range from $365 to $410, with a Hold rating from Truist and a Buy rating from BTIG and Citi.
